- €897.31m
- €513.16m
- €535.18m
Brief: Curevac Announces Solid Progress In Phase 2 Covid-19 And Seasonal Flu Clinical Development Programs In Collaboration With Gsk
German court suspends mRNA patent trial against BioNTech (updated)
Brief: Curevac Says Regional Court Postpones Infringement Ruling Against Biontech
German court suspends mRNA patent trial against BioNTech
CureVac up on expanded patent lawsuit against Pfizer/BioNTech over mRNA tech
Brief: Curevac Strengthens Ongoing Patent Litigations Against Pfizer/BioNTech
U.S. STOCKS ON THE MOVE-CureVac, Aclarion, Baosheng Media
CureVac up after SVB starts coverage with 'outperform' rating
Brief: CureVac NV Says Cash And Cash Equivalents Position Of €617.5 Mln As Of March 31, 2023
CureVac up as US court grants request to transfer COVID vaccine patent case
CureVac files expanded patent lawsuit against Pfizer/BioNTech over mRNA technology (updated)
US court grants CureVac's request to transfer Pfizer/BioNTech's COVID vaccine patent case
Brief: Curevac Announces Dosing Of First Participant In Combined Phase 1/2 Study Of Multivalent, Modified Influenza Vaccine Candidates
Pfizer/BioNTech, Moderna gear up for 2024 London trial over COVID vaccine patents
Brief: Curevac Announces Closing Of $250 Million Follow-On Public Offering Of Common Shares
Brief: Curevac NV Announces Pricing Of Upsized Public Offering Of Common Shares
CureVac drops on planned $200 mln equity offering
Brief: CureVac intends to offer $200 million of its common shares in an underwritten public offering
CureVac up on promising data from flu and COVID-19 mRNA based vaccine